Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery

NCT01623531 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Cardiac Complication During Procedure

Interventions

DRUG: Fibrinogen

Sponsor

Nova Scotia Health Authority